Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +81-29-295-5400Email m-katou@kensei-kai.comPur...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
dpp-4 inhibitor
α-glucosidase inhibitor
metformin
egfr slope
type 2 diabetes
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/8b5d79d40e3f4f0ba712bb5cf5f548e4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8b5d79d40e3f4f0ba712bb5cf5f548e4
record_format dspace
spelling oai:doaj.org-article:8b5d79d40e3f4f0ba712bb5cf5f548e42021-12-02T11:09:32ZAdd-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study1178-7007https://doaj.org/article/8b5d79d40e3f4f0ba712bb5cf5f548e42020-10-01T00:00:00Zhttps://www.dovepress.com/add-on-therapy-with-dpp-4-inhibitors-may-improve-renal-function-declin-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +81-29-295-5400Email m-katou@kensei-kai.comPurpose: We retrospectively evaluated the long-term effect of dipeptidyl peptidase (DPP)-4 inhibitors on estimated glomerular filtration rate (eGFR) slopes, and then evaluated the beneficial interaction between DPP-4 inhibitor initiation and baseline use of α-glucosidase inhibitor and/or metformin in patients with diabetic kidney disease.Patients and Methods: Altogether, 1512 patients with type 2 diabetes were receiving DPP-4 inhibitor therapy over 1 year and were followed up for a maximum of 2 years before and after 7 years of treatment. The decline in renal function was estimated as the slope of the individual linear regression line of eGFR over 2-year follow-up. Prescription data on medications before and after DPP-4 inhibitor treatment were examined.Results: The mean length of DPP-4 inhibitor treatment was 5.3 ± 2.6 years. The baseline mean eGFR slope (mL/min/1.73m2/year) was − 2.24 ± 6.05. After DPP-4 inhibitor treatment, mean eGFR slope was significantly improved (− 1.53 ± 6.36, P < 0.01) in patients with type 2 diabetes. This effect appeared more pronounced for baseline use of α-glucosidase inhibitor and/or metformin in patients with diabetic kidney disease. These non-users showed a trend towards attenuation or no effects.Conclusion: In the present study, patients treated with DPP-4 inhibitors had a significantly slower annual loss of kidney function. The benefit appears pronounced in α-glucosidase inhibitor and metformin users with advanced renal dysfunction. These results suggest that the beneficial effects of DPP-4 inhibitors on kidney function may have occurred in the presence of an α-glucosidase inhibitor and/or metformin.Keywords: DPP-4 inhibitor, α-glucosidase inhibitor, metformin, eGFR slope, type 2 diabetesOsonoi TSaito MKoda NDouguchi SNakano TOfuchi KKatoh MDove Medical Pressarticledpp-4 inhibitorα-glucosidase inhibitormetforminegfr slopetype 2 diabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 3497-3506 (2020)
institution DOAJ
collection DOAJ
language EN
topic dpp-4 inhibitor
α-glucosidase inhibitor
metformin
egfr slope
type 2 diabetes
Specialties of internal medicine
RC581-951
spellingShingle dpp-4 inhibitor
α-glucosidase inhibitor
metformin
egfr slope
type 2 diabetes
Specialties of internal medicine
RC581-951
Osonoi T
Saito M
Koda N
Douguchi S
Nakano T
Ofuchi K
Katoh M
Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
description Takeshi Osonoi, Miyoko Saito, Naoya Koda, Satako Douguchi, Takako Nakano, Kensuke Ofuchi, Makoto Katoh Naka Kinen Clinic, Ibaraki, JapanCorrespondence: Makoto KatohNaka Kinen Clinic, 745-5 Nakadai, Naka-Shi, Ibaraki 311-0113, JapanTel +81-29-353-2800Fax +81-29-295-5400Email m-katou@kensei-kai.comPurpose: We retrospectively evaluated the long-term effect of dipeptidyl peptidase (DPP)-4 inhibitors on estimated glomerular filtration rate (eGFR) slopes, and then evaluated the beneficial interaction between DPP-4 inhibitor initiation and baseline use of α-glucosidase inhibitor and/or metformin in patients with diabetic kidney disease.Patients and Methods: Altogether, 1512 patients with type 2 diabetes were receiving DPP-4 inhibitor therapy over 1 year and were followed up for a maximum of 2 years before and after 7 years of treatment. The decline in renal function was estimated as the slope of the individual linear regression line of eGFR over 2-year follow-up. Prescription data on medications before and after DPP-4 inhibitor treatment were examined.Results: The mean length of DPP-4 inhibitor treatment was 5.3 ± 2.6 years. The baseline mean eGFR slope (mL/min/1.73m2/year) was − 2.24 ± 6.05. After DPP-4 inhibitor treatment, mean eGFR slope was significantly improved (− 1.53 ± 6.36, P < 0.01) in patients with type 2 diabetes. This effect appeared more pronounced for baseline use of α-glucosidase inhibitor and/or metformin in patients with diabetic kidney disease. These non-users showed a trend towards attenuation or no effects.Conclusion: In the present study, patients treated with DPP-4 inhibitors had a significantly slower annual loss of kidney function. The benefit appears pronounced in α-glucosidase inhibitor and metformin users with advanced renal dysfunction. These results suggest that the beneficial effects of DPP-4 inhibitors on kidney function may have occurred in the presence of an α-glucosidase inhibitor and/or metformin.Keywords: DPP-4 inhibitor, α-glucosidase inhibitor, metformin, eGFR slope, type 2 diabetes
format article
author Osonoi T
Saito M
Koda N
Douguchi S
Nakano T
Ofuchi K
Katoh M
author_facet Osonoi T
Saito M
Koda N
Douguchi S
Nakano T
Ofuchi K
Katoh M
author_sort Osonoi T
title Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
title_short Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
title_full Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
title_fullStr Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
title_full_unstemmed Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
title_sort add-on therapy with dpp-4 inhibitors may improve renal function decline in α-glucosidase inhibitor and metformin users: a retrospective observational study
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/8b5d79d40e3f4f0ba712bb5cf5f548e4
work_keys_str_mv AT osonoit addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT saitom addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT kodan addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT douguchis addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT nakanot addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT ofuchik addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
AT katohm addontherapywithdpp4inhibitorsmayimproverenalfunctiondeclineinalphaglucosidaseinhibitorandmetforminusersaretrospectiveobservationalstudy
_version_ 1718396170696392704

Ejemplares similares